Cannabis use and premorbid functioning as predictors of poorer neurocognition in schizophrenia spectrum disorder

Schizophrenia Research

Volumn 143, Issue 1, 2013, Pages 84-89

  Ringen, P Andreas ^a   Melle, Ingrid ^a,b   Berg, Akiah O ^a,b   Agartz, Ingrid ^a,b,c   Spigset, Olav ^d,e   Simonsen, Carmen ^a   Sundet, Kjetil ^a,b   Andreassen, Ole A ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Cannabis; Neurocognitive functioning; Premorbid functioning; Schizophrenia; Urine samples

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; COCAINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANNABIS ADDICTION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG ABUSE; DRUG URINE LEVEL; DSM-IV; HUMAN; MAJOR CLINICAL STUDY; NORWAY; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBSTANCE ABUSE; URINALYSIS;

ADAPTATION, PSYCHOLOGICAL; ADULT; ATTENTION; CANNABINOIDS; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MEMORY; NEUROPSYCHOLOGICAL TESTS; NORWAY; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VERBAL LEARNING; YOUNG ADULT;

EID: 84871937717     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.10.021     Document Type: Article

References (38)

1. Bagoien G., Morken G., Zahlsen K., Aamo T., Spigset O. Evaluation of a urine on-site drugs of abuse screening test in patients admitted to a psychiatric emergency unit. J. Clin. Psychopharmacol. 2009, 29:248-254.
2. Barak Y., Baruch Y., Achiron A., Aizenberg D. Suicide attempts of schizophrenia patients: A case-controlled study in tertiary care. J. Psychiatr. Res. 2008, 42:822-826.
3. Bhattacharyya S., Morrison P.D., Fusar-Poli P., Martin-Santos R., Borgwardt S., Winton-Brown T., Nosarti C., O' Carroll C.M., Seal M., Allen P., Mehta M.A., Stone J.M., Tunstall N., Giampietro V., Kapur S., Murray R.M., Zuardi A.W., Crippa J.A., Atakan Z., McGuire P.K. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35:764-774.
4. Brill N., Reichenberg A., Rabinowitz J., Harary E., Lubin G., Davidson M., Weiser M. Accuracy of self-reported premorbid functioning in schizophrenia. Schizophr. Res. 2007, 97:103-108.
5. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982, 8:470-484.
6. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 2001, 50:71-83.
7. Del Boca F.K., Noll J.A. Truth or consequences: the validity of self-report data in health services research on addictions. Addiction 2000, 95(Suppl. 3):S347-S360.
8. Delis D., Kramer J.K., Kaplan E., Ober B. California Verbal Learning Test, second edition (CVLT-II). Norwegian manual supplement 2004, Pearson Assessment, Stockholm.
9. Delis D., Kaplan E., Kramer J.K. The Delis-Kaplan Executive Function System (D-KEFS). Norwegian manual supplement 2005, Pearson Assessment, Stockholm.
10. Dixon L., Haas G., Weiden P.J., Sweeney J., Frances A.J. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry 1991, 148:224-230.
11. D'Souza D.C., Perry E., Macdougall L., Ammerman Y., Cooper T., Wu Y.T., Braley G., Gueorguieva R., Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
12. D'Souza D.C., Bi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 2005, 57:594-608.
13. Green A.I., Drake R.E., Brunette M.F., Noordsy D.L. Schizophrenia and co-occurring substance use disorder. Am. J. Psychiatry 2007, 164:402-408.
14. Haatveit B.C., Sundet K., Hugdahl K., Ueland T., Melle I., Andreassen O.A. The validity of d prime as a working memory index: results from the "Bergen n-back task". J. Clin. Exp. Neuropsychol 2010, 1-10.
15. Ho B.C., Wassink T.H., Ziebell S., Andreasen N.C. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr. Res. 2011, 128:66-75.
16. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
17. Lambert M., Conus P., Lubman D.I., Wade D., Yuen H., Moritz S., Naber D., McGorry P.D., Schimmelmann B.G. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr. Scand. 2005, 112:141-148.
18. Larsen T.K., Friis S., Haahr U., Johannessen J.O., Melle I., Opjordsmoen S., Rund B.R., Simonsen E., Vaglum P.V., McGlashan T.H. Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. Br. J. Psychiatry 2004, 185:108-115.
19. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry 1994, 51:273-279.
20. Loberg E.M., Hugdahl K. Cannabis use and cognition in schizophrenia. Front. Hum. Neurosci. 2009, 3:53.
21. Lowe R.H., Abraham T.T., Darwin W.D., Herning R., Cadet J.L., Huestis M.A. Extended urinary [Delta]9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009, 105:24-32.
22. Margolese H.C., Malchy L., Negrete J.C., Tempier R., Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr. Res. 2004, 67:157-166.
23. Minozzi S., Davoli M., Bargagli A.M., Amato L., Vecchi S., Perucci C.A. An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug Alcohol Rev. 2010, 29:304-317.
24. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
25. Morrison P.D., Zois V., McKeown D.A., Lee T.D., Holt D.W., Powell J.F., Kapur S., Murray R.M. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol. Med. 2009, 39:1607-1616.
26. Murray R.M., Morrison P.D., Henquet C., Di F.M. Cannabis, the mind and society: the hash realities. Nat. Rev. Neurosci. 2007, 8:885-895.
27. Pedersen G., Hagtvet K.A., Karterud S. Generalizability studies of the Global Assessment of Functioning-Split version. Compr. Psychiatry 2007, 48:88-94.
28. Rabin R.A., Zakzanis K.K., George T.P. The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophr. Res. 2011, 128:111-116.
29. Ringen P.A., Lagerberg T.V., Birkenaes A.B., Engh J.A., Faerden A., Jonsdottir H., Nesvag R., Friis S., Opjordsmoen S., Larsen F., Melle I., Andreassen O.A. Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychol. Med. 2008, 38(9):1241-1249.
30. Salyers M.P., Mueser K.T. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr. Res. 2001, 48:109-123.
31. SAMHSA Reports on specific drugs 2011, Office of Applied Studies (OAS), Substance Abuse and Mental Health Services Administration (SAMHSA).US Department of Health and Mental Services, Rockville (MD), USA, (12-10-2011).
32. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979, 86:420-428.
33. Simonsen C., Sundet K., Vaskinn A., Birkenaes A.B., Engh J.A., Faerden A., Jonsdottir H., Ringen P.A., Opjordsmoen S., Melle I., Friis S., Andreassen O.A. Neurocognitive Dysfunction in Bipolar and Schizophrenia Spectrum Disorders Depends on History of Psychosis Rather Than Diagnostic Group. Schizophr. Bull. 2011, 37(1):73-83.
34. Ventura J., Liberman R.P., Green M.F., Shaner A., Mintz J. Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res. 1998, 79:163-173.
35. Wechsler D. Wechsler Adult Intelligence Scale, third edition (WAIS-III). Norwegian manual supplement 2003, Pearson Assessment, Stockholm.
36. Wechsler D. Wechsler Abbreviated Scale of Intelligence (WASI). Norwegian manual supplement 2007, Pearson Assessment, Stockholm.
37. Weiss R.D., Najavits L.M., Greenfield S.F., Soto J.A., Shaw S.R., Wyner D. Validity of substance use self-reports in dually diagnosed outpatients. Am. J. Psychiatry 1998, 155:127-128.
38. Yucel M., Bora E., Lubman D.I., Solowij N., Brewer W.J., Cotton S.M., Conus P., Takagi M.J., Fornito A., Wood S.J., McGorry P.D., Pantelis C. The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample. Schizophr. Bull. 2012, 38(2):316-330.